Angiocrine Bioscience, Inc.

10 articles with Angiocrine Bioscience, Inc.

• Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial Data during the Annual Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

  2/13/2023

  Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that it has been selected by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) for a poster presentation on its Phase 3 registration study AB-205-301 (E- CELERATE).

• Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial

  12/19/2022

  Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT).

• Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology (ASH)

  12/9/2022

  Angiocrine Bioscience, Inc. today announced that it has been selected by the American Society of Hematology (ASH) for a poster presentation on its Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT).

• Angiocrine Bioscience Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of AB-205 in Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) and Completion of Series B Financing

  3/29/2022

  Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT).

• Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation

  3/12/2021

   Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the European Society for Blood and Marrow Transplantation (EBMT) for an oral presentation of from AB-205-001, a Phase 1b /2 study to prevent progression to severe organ toxicities in lymphoma subjects

• Angiocrine Bioscience Announces Oral Presentation of Intravenous AB-205 Data during the Annual Transplantation & Cellular Therapy Meetings of ASCT and CIBMTR

  2/5/2021

  Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) has selected Angiocrine's AB-205 Phase 1b /2 study results for an oral presentation. 

• Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 62nd Annual Meeting of the American Society of Hematology (ASH)

  12/4/2020

  Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the American Society of Hematology (ASH) for an oral presentation on the preliminary results of a Phase 1b/2 study of AB-205 to prevent or reduce severe organ toxicities associated with high-dose therapy followed by autologous hematopoietic cell transplantation

• Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL® Cell Therapy) to Treat Organ Vascular Niche Injuries for the Prevention of Severe Toxicities in Lymphoma Patients

  11/11/2020

  Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation for AB-205, for "the treatment of organ vascular niche injuries to prevent or reduce severe regimen-related toxicities (SRRT) in pa

• Angiocrine Bioscience Announces Collaboration For Clinical Cell Manufacturing Platform With Terumo BCT

  1/11/2016

• Angiocrine Bioscience Licenses New Stem Cell Technology From Weill Cornell Medical College

  8/21/2014